Christopher Yohn
Family Medicine · Mansfield, OHNPI 1063945533
Payments from drug & device makers
Across 87 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$315
- Gilead$270
- Indivior Inc.$149
- Phathom Pharmaceuticals, Inc.$105
- Braeburn Inc.$99
- Bayer$76
- plus $489 from 17 others
What the payments were for
- Food & beverage$1,502100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $315 |
| Gilead | 17 | $270 |
| Indivior Inc. | 7 | $149 |
| Phathom Pharmaceuticals, Inc. | 6 | $105 |
| Braeburn Inc. | 5 | $99 |
| Bayer | 4 | $76 |
| Alkermes, Inc. | 4 | $67 |
| Edwards Lifesciences | 2 | $50 |
| Exact Sciences | 3 | $48 |
| GSK | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $35 |
| Merck | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Pfizer | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
How this compares
$1,502 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $27,611 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $21,023 |
| JardianceEmpagliflozin | 14 | $17,829 |
| Spiriva HandihalerTiotropium Bromide | 15 | $12,489 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $11,363 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,231 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $3,788 |
| Varenicline Tartrate | 13 | $2,819 |
| Aripiprazole | 15 | $1,562 |
| Atorvastatin Calcium | 182 | $1,559 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $1,496 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,450 |
| Omeprazole | 105 | $1,178 |
| Oxybutynin Chloride ErOxybutynin Chloride | 17 | $1,141 |
| Losartan Potassium | 105 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta | $47 | $32,38546 claims |
| Novo NordiskOzempic | $15 | $27,61117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Mansfield
- Brett TowardMansfield$41K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.